#pharmaceutical pricing

2 stories

#advanced cancer #astrazeneca #breast cancer #cancer treatment #compounding pharmacies #daiichi sankyo #drug approval #drug safety #eli lilly #england #enhertu #fda regulation

The risky boom in cut-price weight-loss drugs
Compounding pharmacies are flooding the market with cheaper versions of GLP-1 drugs, but with far less oversight than brand-name alternatives.
TIME · 3m
Life-extending breast cancer drug now on NHS
After price negotiations, thousands of women with advanced HER2-low breast cancer will access Enhertu on the NHS from Thursday.
the Guardian · 1m